Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829637 | 1.00 | NR1H2 (0.49) | NR1H2NR1H3RIPK1BACE1TMEM97 | |
| SCHEMBL14829403 | 1.00 | NR1H2 (0.49) | NR1H2NR1H3RIPK1BACE1TMEM97 | |
| SCHEMBL14916072 | 0.89 | CFB (0.42) | NR1H2NR1H3BACE1USP2SMN1; SMN2 | |
| SCHEMBL2386027 | 0.87 | NR1H2 (0.43) | NR1H2NR1H3USP2SMN1; SMN2GPR119 | |
| SCHEMBL2386023 | 0.87 | NR1H2 (0.43) | NR1H2NR1H3USP2SMN1; SMN2GPR119 | |
| SCHEMBL21224528 | 0.87 | USP2 (0.41) | NR1H2NR1H3BACE1TMEM97SIGMAR1 | |
| SCHEMBL3398818 | 0.87 | NR1H2 (0.43) | NR1H2NR1H3USP2SMN1; SMN2GPR119 | |
| SCHEMBL21682785 | 0.87 | NR1H2 (0.50) | NR1H2NR1H3BACE1USP2SMN1; SMN2 | |
| SCHEMBL20879577 | 0.86 | NR1H2 (0.46) | NR1H2NR1H3RIPK1GPR119HCRTR2 | |
| SCHEMBL18394698 | 0.86 | NPC1 (0.47) | NR1H2NR1H3USP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NR1H2 3187/4885NR1H3 3488/4885RIPK1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.